8-K: Lantheus Agrees to $8B Acquisition by Curium

Lantheus Holdings, Inc. announced its second quarter 2026 financial results and a definitive agreement to be acquired by Curium US Holdings LLC for up to $8.0 billion.

Summary

• Lantheus Holdings reported second quarter 2026 worldwide revenue of $388.2 million, a 2.7% increase year-over-year.
• GAAP fully diluted earnings per share were $1.11, a slight decrease from $1.12 in the prior year period.
• Adjusted fully diluted earnings per share were $1.55, down from $1.57 in the second quarter of 2025.
• The company entered into a definitive agreement on August 3, 2026, to be acquired by Curium US Holdings LLC for $102.50 per share in cash plus up to $12.00 per share in Contingent Value Rights (CVRs).
• The total transaction value is up to approximately $8.0 billion.
• Lantheus has suspended its full-year 2026 financial guidance due to the pending acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily driven by the significant acquisition offer, which provides a clear exit for shareholders at a premium. However, the slight dip in quarterly revenue and earnings, alongside the decrease in PYLARIFY sales, introduces a note of caution.

Positives

• Agreement to be acquired by Curium for up to $8.0 billion, representing a significant premium for shareholders.
• Worldwide revenue increased by 2.7% to $388.2 million in the second quarter of 2026.
• Sales of DEFINITY increased by 5.2% to $88.3 million.
• Operating income increased by 13.9% to $100.2 million.
• Net cash provided by operating activities was $92.2 million, and free cash flow was $89.9 million for the quarter.
• Cash and cash equivalents increased significantly to $593.3 million as of June 30, 2026, from $359.1 million at the end of 2025.

Negatives

• PYLARIFY sales decreased by 4.1% to $240.4 million.
• GAAP net income decreased by 4.7% to $75.0 million.
• GAAP fully diluted earnings per share decreased by 0.9% to $1.11.
• Adjusted net income decreased by 5.1% to $104.9 million.
• Adjusted fully diluted earnings per share decreased by 1.3% to $1.55.

Risks

• Continued market expansion, penetration, and reimbursement for established products in a competitive environment.
• Ability to complete technology transfer for PYLARIFY TruVu and obtain FDA approval for manufacturing facilities.
• Availability of raw materials, key components, equipment, and manufacturing time slots.
• Ability to satisfy obligations under clinical development partnerships and license agreements.
• Successful integration of acquisitions, including potential unforeseen expenses and liabilities.
• Obtaining FDA approval for LNTH-2501 and successfully commercializing it, including resolving facility inspection-related conditions.
• Successfully defending the favorable District Court ruling for PNT2003, which is currently on appeal.
• Risks and uncertainties associated with the pending acquisition by Curium, including the ability to satisfy closing conditions and potential termination of the merger agreement.

Future Outlook

Lantheus has suspended its previously issued full year 2026 financial guidance due to the pending acquisition by Curium. No new guidance is provided.

Management Comments

• "Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries."
• The Board of Directors of Lantheus has unanimously approved the transaction.

Industry Context

StockSavvy.ai notes that this acquisition signifies a major consolidation trend within the radiopharmaceutical sector, aiming to create a larger, more integrated entity capable of broader global reach in both diagnostic and therapeutic areas. The proposed merger with Curium, another significant player, highlights the industry's drive towards scale and comprehensive offerings.

Comparison to Industry Standards

• The acquisition valuation of up to $8.0 billion represents a substantial multiple, reflecting the strategic importance and growth potential of radiopharmaceuticals.
• The combined entity's presence in over 70 countries indicates an ambition to achieve global leadership, surpassing many current regional players.
• The focus on both diagnostics and therapeutics aligns with industry trends towards integrated cancer care solutions.

Legal Proceedings

• Alleged stockholder actions have been filed against the company, with timing and outcomes uncertain.

Stakeholder Impact

• Shareholders: Potential for significant return through the all-cash transaction and CVRs, offering up to $114.50 per share.
• Employees: Future employment and integration into the combined Curium-Lantheus entity remain uncertain pending transaction completion.
• Customers: Potential for expanded product offerings and global support from the combined company.
• Creditors: The acquisition structure and financing will determine the impact on existing debt obligations.

Next Steps

• Shareholders will receive definitive proxy statements regarding the proposed acquisition.
• The transaction is subject to closing conditions outlined in the merger agreement.
• Lantheus will continue to operate as a standalone entity until the transaction closes.

Key Dates

Recommendation

The acquisition offer provides a clear, premium exit for shareholders, making a 'hold' appropriate to await closing. While quarterly results show some pressure on key products like PYLARIFY, the overall deal value is compelling. Investors should monitor the closing conditions and the potential value of the CVRs.

Keywords

radiopharmaceutical, acquisition, merger, Curium, PYLARIFY, DEFINITY, Neuraceq, financial results